Japanese stocks traded here fared well across the board.

But the medical stocks fared better, buoyed by analysts' recommendations.

European stocks fared better, but their returns for the quarter were lower than the gains they put up in the second half of last year.

Led by energy, technology and health care (otherwise known as biotechnology), small stocks fared well.

The company's stock has fared badly, slipping to $19.375, from around $48 two years ago and $35 last summer.

Moreover, the highest-quality domestic stocks have fared better than that.

In a number of midyear stretches, stocks have fared much better.

Like many hotel companies, for much of the last year Starwood's stock has fared poorly.

Mexican stocks traded in New York did not fare as well.

And some stocks fare poorly even though the company is buying.